9. Pharmacological Approaches to Glycemic Management: Standards of Medical Care in Diabetes – 2021.
diabetes treatment. 2021; 44: S111-S124
2019 ESC Guidelines on Diabetes, Prediabetes and Cardiovascular Disease developed in collaboration with EASD.
Your heart J 2020; 41: 255-323
2019 update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
diabetology. 2020; 63: 221-228
Cardiovascular, mortality, and renal outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials.
Lancet Diabetes Endocrinol. 2021; 9: 653-662
The effect of exenatide once weekly on the estimated slope of glomerular filtration rate depends on baseline renal risk: a post hoc analysis of the EXSCEL study.
diabetes obesity metab. 2020; 22: 2493-2498
Effect of glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on renal outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER.
Traffic. 2022; 145: 575-585
Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: Exploratory Analysis of AWARD-7.
kidney360. 2020; 2: 254-262
Glucose-dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution independent of insulin: the ADDITION-PRO study.
J Clin Endocrinol Metab. 2016; 101: 485-493
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a phase 2 randomized, placebo-controlled and active comparative study.
Lancet. 2018; 392: 2180-2193
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomized phase 3 study.
Lancet. 2021; 398: 143-155
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.
N Engl. J Med. 2021; 385: 503-515
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a phase 3, randomized, open-label, parallel-group study.
Lancet. 2021; 398: 583-598
Effect of subcutaneous tirzepatide compared to placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the randomized clinical trial SURPASS-5.
JAMA. 2022; 327: 534-545
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomized, open-label, parallel-group, multicenter, phase 3 study.
Lancet. 2021; 398: 1811-1824
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
diabetes obesity metab. 2020; 22: 2451-2459
Tirzepatide risk assessment for cardiovascular events: a pre-specified meta-analysis.
Nat Med. 2022; 28: 591-598
The Treat-to-Target study: randomized addition of glargine or NPH human insulin to the oral therapy of patients with type 2 diabetes.
diabetes treatment. 2003; 26: 3080-3086
A new equation for estimating glomerular filtration rate.
Ann Intern Med. 2009; 150: 604-612
The dual glucose-dependent insulinotropic polypeptide and the glucagon-like peptide-1 receptor agonist tirzepatide improve cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis.
diabetes obesity metab. 2022; 24: 148-153
GFR increase as a surrogate endpoint for renal disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials.
J.Am. society nephrol. 2019; 30: 1735-1745
Different eGFR decline thresholds and renal effects of canagliflozin: data from the CANVAS program.
J.Am. society nephrol. 2020; 31: 2446-2456
Ertugliflozin and slope of chronic eGFR.
Clin J Am Soc Nephrol. 2021; 16: 1345-1354
An acute drop in estimated glomerular filtration rate during treatment with losartan predicts a slower decline in long-term renal function.
kidney internal 2011; 80: 282-287
Findings from the CREDENCE study indicate an acute drop in estimated glomerular filtration rate during canagliflozin treatment with implications for clinical practice.
kidney internal 2021; 99: 999-1009
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance and treatment.
J.Am. society nephrol. 2017; 28: 1023-1039
Mechanisms mediating the diuretic and natriuretic effects of the incretin hormone glucagon-like peptide-1.
Am J Physiol Renal Physiol. 2011; 301: F355-F363
Change in albuminuria as a surrogate endpoint for renal disease progression: a meta-analysis of treatment effects in randomized clinical trials.
Lancet Diabetes Endocrinol. 2019; 7: 128-139
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
kidney internal 2020; 98: S1-115
Early change in albuminuria with canagliflozin predicts renal and cardiovascular outcomes: a post hoc analysis from the CREDENCE study.
J.Am. society nephrol. 2020; 31: 2925-2936
Reappraisal of GIP pharmacology for metabolic diseases.
Trends Mol Med. 2016; 22: 359-376
Inflammation of perinephric adipose tissue: new evidence linking metabolic dysfunction to renal disease.
Front Endocrinol (Lausanne). 2021; 12707126
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
Nat Rev Nephrol. 2017; 13: 605-628
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.
Nat Rev Nephrol. 2021; 17: 227-244
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the randomized, placebo-controlled REWIND study.
Lancet. 2019; 394: 131-138
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes.
N Engl. J Med. 2021; 385: 896-907
Liraglutide and renal outcomes in type 2 diabetes.
N Engl. J Med. 2017; 377: 839-848
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomized, placebo-controlled study.
Lancet. 2019; 393: 1937-1947
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
N Engl. J Med. 2019; 380: 2295-2306
Dapagliflozin in patients with chronic kidney disease.
N Engl. J Med. 2020; 383: 1436-1446
The endothelin antagonist atrasentan reduces residual albuminuria in patients with type 2 diabetic nephropathy.
J.Am. society nephrol. 2014; 25: 1083-1093
Albuminuria-lowering effects of dapagliflozin alone and in combination with saxagliptin and effects of dapagliflozin and saxagliptin on glycemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomized, double-blind, placebo-controlled study.
Lancet Diabetes Endocrinol. 2019; 7: 429-441
Efficacy and safety of canagliflozin in patients with type 2 diabetes and chronic kidney disease.
diabetes obesity metab. 2013; fifteen: 463-473
Efficacy and safety of liraglutide compared to placebo as add-on therapy to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial.
diabetes treatment. 2016; 39: 222-230
Basal insulin glargine and microvascular outcomes in subjects with dysglycemia: results from the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) study.
diabetology. 2014; 57: 1325-1331
